These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
400 related articles for article (PubMed ID: 20070634)
1. Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model list of essential medicines. Twagirumukiza M; Annemans L; Kips JG; Bienvenu E; Van Bortel LM Trop Med Int Health; 2010 Mar; 15(3):350-61. PubMed ID: 20070634 [TBL] [Abstract][Full Text] [Related]
2. Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China. Yang H; Dib HH; Zhu M; Qi G; Zhang X Health Policy Plan; 2010 May; 25(3):219-29. PubMed ID: 19955093 [TBL] [Abstract][Full Text] [Related]
3. Prices & availability of common medicines at six sites in India using a standard methodology. Kotwani A; Ewen M; Dey D; Iyer S; Lakshmi PK; Patel A; Raman K; Singhal GL; Thawani V; Tripathi S; Laing R Indian J Med Res; 2007 May; 125(5):645-54. PubMed ID: 17642500 [TBL] [Abstract][Full Text] [Related]
4. Implementing an essential medicines list: effects on pricing and utilization in West Bank, Palestine. Hamidi S; Younis MZ; Forgione DA J Health Care Finance; 2008; 34(4):10-30. PubMed ID: 21110478 [TBL] [Abstract][Full Text] [Related]
5. Providing affordable essential medicines to African households: the missing policies and institutions for price containment. Tetteh Ek Soc Sci Med; 2008 Feb; 66(3):569-81. PubMed ID: 18023953 [TBL] [Abstract][Full Text] [Related]
6. Availability, prices and affordability of essential medicines for treatment of diabetes and hypertension in private pharmacies in Zambia. Kaiser AH; Hehman L; Forsberg BC; Simangolwa WM; Sundewall J PLoS One; 2019; 14(12):e0226169. PubMed ID: 31834889 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology. Saeed A; Saeed H; Saleem Z; Fang Y; Babar ZU PLoS One; 2019; 14(4):e0216122. PubMed ID: 31022276 [TBL] [Abstract][Full Text] [Related]
8. Price discrimination in essential medicines: evidence from International Drug Price Indicator Guide data. Hanlon M; Zhang R Int Health; 2013 Mar; 5(1):58-63. PubMed ID: 24029847 [TBL] [Abstract][Full Text] [Related]
9. Spending on medicines in Israel in an international context. Sax P Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459 [TBL] [Abstract][Full Text] [Related]
10. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China. Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348 [TBL] [Abstract][Full Text] [Related]
11. A quantitative comparison of essential cardiovascular medicines from countries in the Southern African Development Community to the WHO model essential medicines list. Naicker I; Suleman F; Perumal-Pillay VA J Pharm Policy Pract; 2022 Dec; 15(1):97. PubMed ID: 36482421 [TBL] [Abstract][Full Text] [Related]
12. Availability of essential medicines in Ethiopia: an efficiency-equity trade-off? Carasso BS; Lagarde M; Tesfaye A; Palmer N Trop Med Int Health; 2009 Nov; 14(11):1394-400. PubMed ID: 19754520 [TBL] [Abstract][Full Text] [Related]
13. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Cameron A; Ewen M; Ross-Degnan D; Ball D; Laing R Lancet; 2009 Jan; 373(9659):240-9. PubMed ID: 19042012 [TBL] [Abstract][Full Text] [Related]
14. High medicine prices and poor affordability. Suh GH Curr Opin Psychiatry; 2011 Jul; 24(4):341-5. PubMed ID: 21532479 [TBL] [Abstract][Full Text] [Related]
15. Effect of privatization of the drug distribution system on drug prices in Malaysia. Babar ZD; Izham MI Public Health; 2009 Aug; 123(8):523-33. PubMed ID: 19665741 [TBL] [Abstract][Full Text] [Related]
16. Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability. Husain MJ; Datta BK; Kostova D; Joseph KT; Asma S; Richter P; Jaffe MG; Kishore SP J Am Heart Assoc; 2020 May; 9(9):e015302. PubMed ID: 32338557 [TBL] [Abstract][Full Text] [Related]
17. Drugs for STD management in developing countries: choice, procurement, cost, and financing. Van der Veen F; Fransen L Sex Transm Infect; 1998 Jun; 74 Suppl 1():S166-74. PubMed ID: 10023369 [TBL] [Abstract][Full Text] [Related]
18. Innovation and the WHO's essential medicines list: giving credit where credit is due. Wertheimer AI; Santella TM Res Social Adm Pharm; 2007 Mar; 3(1):137-44. PubMed ID: 17350562 [No Abstract] [Full Text] [Related]
19. Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs. Laing RO; McGoldrick KM Int J Tuberc Lung Dis; 2000 Dec; 4(12 Suppl 2):S194-207. PubMed ID: 11144553 [TBL] [Abstract][Full Text] [Related]
20. [Why drug prices are high in sub-Saharan Africa. Analysis of price structure: the case of Senegal]. Guimier JM; Candau D; Garenne M; Teulières L Sante; 2005; 15(1):41-52. PubMed ID: 15919632 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]